Search

Displaying results 3221 - 3230 of 7706 in total
  1. Drug

    Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB18750
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

    Synonyms: Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)
  2. Drug

    Influenza A virus A/District of Columbia/27/2023 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB22669
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  3. Drug

    Influenza A virus A/Victoria/800/2024 CVR-289 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB22671
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  4. Drug

    Influenza A virus A/Perth/722/2024 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB31654
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  5. Drug

    Endostatin

    go.drugbank.com/drugs/DB06423
    Investigational

  6. Drug

    Midecamycin

    go.drugbank.com/drugs/DB13456
    Investigational

    In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar.

  7. Drug

    Isosulfan blue

    go.drugbank.com/drugs/DB09136
    ApprovedInvestigational

  8. Target

    (3R)-3-hydroxyacyl-CoA dehydrogenase

    go.drugbank.com/bio_entities/BE0000578
    TargetHumans

    Alpha-subunit of the KAR complex that acts as a scaffold protein required for the stability of carbonyl reductase type-4 (CBR4, beta-subunit of the KAR complex) and for its 3-ketoacyl-ACP reductase activity … Required for the solubility and assembly of the heterotetramer 3-ketoacyl-[acyl carrier protein] (ACP) reductase functional complex (KAR or KAR1) that forms part of the mitochondrial fatty acid synthase

    Synonyms: KAR alpha subunit
  9. Drug

    Teglarinad chloride

    go.drugbank.com/drugs/DB05217
    Investigational

    GMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic activity. In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond....

  10. Drug

    JNJ-37822681

    go.drugbank.com/drugs/DB12579
    Investigational

    JNJ-37822681 has been used in trials studying the treatment of Schizophrenia.

    Categories: Dopamine D2 Receptor Antagonists